版本:
中国

BRIEF-Soligenix receives FDA protocol clearance of pivotal phase 3 clinical trial of sgx942

May 3 Soligenix Inc:

* Soligenix receives FDA protocol clearance of pivotal phase 3 clinical trial of sgx942 for the treatment of oral mucositis in head and neck cancer patients

* Soligenix Inc- Soligenix plans to begin the study in Q2 of 2017 Source text for Eikon: Further company coverage:

我们的标准: 汤森路透“信任原则

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐